July 18, 2017
Indian Biosimilar

Indian Biosimilar – Slow but Steady?

The white paper attempts to infer the biosimilar play of India-based biosimilar developers. It explores plausible scenarios for Indian developers entering the lucrative US and EU biosimilar market based on the current situation analysis of major biosimilar developers.
June 5, 2017

India In The Global Biosimilar Play

In part 1 of this two part paper, we indicated that even as the western markets are opening up to mAb biosimilars, Indian biosimilar companies have focused on home turfs. In the absence of a crystal ball and presence of several caveats, there is no telling how the market will shape […]